Sierra Oncology (SRRA +7.2%) announces long-term
safety and dose intensity data on momelotinib, a JAK1, JAK2 and ACVR1
inhibitor, in more than 550 myelofibrosis patients. The results were
presented at EHA.
Over periods as long as 10 years, increases in
hemoglobin levels were sustained compared to decreases in those
receiving Incyte’s Jakafi (ruxolitinib). Higher mean platelet counts
were also observed in patients receiving momelotinib.
No new safety signals or evidence of cumulative toxicity have been observed, including patients receiving full-dose momelotinib.
https://seekingalpha.com/news/3582652-sierra-oncologys-momelotinib-shows-long-term-benefit-in-myelofibrosis
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.